Data presentations at 2023 winter clinical dermatology conference - hawaii® support clinical value of castle biosciences' skin cancer test portfolio

Friendswood, texas--( business wire )--castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, today announced that new data supporting the clinical value of the company's skin cancer test portfolio is being shared in poster presentations at the 2023 winter clinical dermatology conference - hawaii®, being held jan. 13-18 in kohala coast, hawaii.
CSTL Ratings Summary
CSTL Quant Ranking